Long, GV; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Fernandez, ANAMA; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HAH; Ascierto, PA; Ribas, A; Flaherty, K; Lee, DY; Masood, A; Gasal, E; Dummer, R.
The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAFV600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
J CLIN ONCOL. 2019; 37(15):
Doi: 10.1200/JCO.2019.37.15_suppl.9531
[Poster]
Web of Science
FullText
FullText_MUG